timothy sykes logo
QNRX Surges As Quoin Raises $50M After Positive Trial Data Thumbnail
G Google News

QNRX Surges As Quoin Raises $50M After Positive Trial Data

TIM SYKES•UPDATED AUG. 29, 2026, 10:06 AM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Quoin Pharmaceuticals Ltd. stocks have been trading up by 10.65 percent amid heightened investor optimism from the most impactful news.

What Traders Need To Know

  • Interim Phase 2/3 data for lead drug QRX003 in Netherton Syndrome showed statistically significant efficacy, with 4 of 6 patients hitting the main skin-improvement goal and key secondary measures.
  • The company expects QRX003 (conditionally branded QYLEKI) to complete trial enrollment by end-2026, with topline data planned for Q2 2027, framing a clear catalyst timeline.
  • A private placement of up to $50M, including $30.8M upfront and potential $19.2M from warrants at $6.10, extends cash runway into 2H 2029 but brings dilution and warrant overhang.
  • Shares spiked roughly 18%–29% after the data and financing, signaling strong momentum and event-driven volatility in QNRX.
  • Q2 2026 showed a wider-than-expected loss as R&D climbed, while the pipeline broadened with FDA-cleared trials in Peeling Skin Syndrome and advancement of QRX009.

Candlestick Chart

Weekly Update Aug 24 – Aug 28, 2026: On Saturday, August 29, 2026 Quoin Pharmaceuticals Ltd. stock [NASDAQ: QNRX] is trending up by 10.65%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Quoin (QNRX) is a micro-cap, single-asset–dominant rare-disease platform with extremely weak fundamentals but improving liquidity. LTM metrics are deeply negative (ROA -178%, ROE -576%), reflecting a pre-revenue R&D model and heavy accumulated deficit (retained earnings -$66M) with negative equity of -$1.2M. Cash of ~$1.8M and current ratio 1.8x were inadequate pre-raise, but the up-to-$50M private placement meaningfully extends runway and offsets near-term solvency risk despite substantial dilution.

Technically, QNRX has shifted from consolidation to a nascent uptrend following the financing and data catalysts. This week’s tape shows a push from ~$5.07 to a $6.32 high, closing at $5.70, with expanding intraday ranges and elevated volume on the breakout day, confirming institutional participation. The $4.85–5.00 zone, anchored near the $4.88 placement price, is now the key actionable support; tactical long entries above $5 with stops below $4.80 and a first upside target at $6.10 (warrant strike) are justified.

Near term, QNRX trades as a binary clinical and financing story, but current news flow is strongly favorable versus biotech benchmarks. Statistically significant interim Phase 2/3 QRX003 data in Netherton, conditional brand-name approval (QYLEKI), and an extended cash runway into at least 2029 position the company ahead of many early-stage peers on risk-adjusted value. I expect continued volatility but a constructive bias, with technical resistance at $6.10 then ~$7.50; risk-reward to those levels is attractive.

More Breaking News

Quick Financial Overview

Quoin Pharmaceuticals Ltd. (QNRX) is trading as a classic event-driven micro-cap biotech. On the weekly tape, the stock climbed from around $5.07 to $5.70 into the latest news burst, with a clear expansion in range as the high pushed to $6.32. That tightening-and-pop behavior is what you expect when traders position ahead of binary clinical data and then react to a positive surprise.

Intraday, the 5-minute snapshot showing a spike from the low-$7s to above $8 before settling near $6.12 reflects aggressive opening demand followed by profit taking. For short-term traders, this means liquidity is improving but swings are wide; bid/ask spreads and slippage matter. The warrant strike at $6.10 also creates a natural reference zone where some supply may appear as holders hedge or lock in gains.

Fundamentally, QNRX remains pre-revenue and deeply loss-making. The latest quarterly data show net income of about -$3.95M and operating cash flow of roughly -$2.23M, with free cash flow similarly negative. Balance sheet metrics such as a current ratio of 1.8 and zero long-term debt are helped by equity funding, but returns on equity and assets are sharply negative, which is normal for a development-stage biotech yet still a reminder that the story is all about future approvals and not current earnings.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”